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Abstract 
Background: Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide. When PPH occurs, 
early identification of bleeding and prompt management using evidence‑based guidelines, can avert most PPH‑
related severe morbidities and deaths. However, adherence to the World Health Organization recommended practices 
remains a critical challenge. A potential solution to inefficient and inconsistent implementation of evidence‑based 
practices is the application of a ‘clinical care bundle’ for PPH management. A clinical care bundle is a set of discrete, 
evidence‑based interventions, administered concurrently, or in rapid succession, to every eligible person, along 
with teamwork, communication, and cooperation. Once triggered, all bundle components must be delivered. The 
E‑MOTIVE project aims to improve the detection and first response management of PPH through the implementa‑
tion of the “E‑MOTIVE” bundle, which consists of (1) Early PPH detection using a calibrated drape, (2) uterine Massage, 
(3) Oxytocic drugs, (4) Tranexamic acid, (5) Intra Venous fluids, and (6) genital tract Examination and escalation when 
necessary. The objective of this paper is to describe the protocol for the formative phase of the E‑MOTIVE project, 
which aims to design an implementation strategy to support the uptake of this bundle into practice.
Methods: We will use behavior change and implementation science frameworks [e.g. capability, opportunity, 
motivation and behavior (COM‑B) and theoretical domains framework (TDF)] to guide data collection and analysis, in 
Kenya, Nigeria, South Africa, Sri Lanka, and Tanzania. There are four methodological components: qualitative inter‑
views; surveys; systematic reviews; and design workshops. We will triangulate findings across data sources, partici‑
pant groups, and countries to explore factors influencing current PPH detection and management, and potentially 
influencing E‑MOTIVE bundle implementation. We will use these findings to develop potential strategies to improve 
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Background
In low resource countries, every six minutes a woman in 
the prime of her life, and often with small children, dies 
from postpartum hemorrhage (PPH) [1]. PPH, defined as 
a blood loss of 500  mL or more following childbirth, is 
the leading cause of maternal death worldwide, account-
ing for 27% of global maternal deaths and affecting 5% of 
all live births [2, 3]. Women who survive PPH are also at 
risk for severe maternal morbidities (organ dysfunctions) 
and longer-term disabilities [4]. The most common cause 
of PPH is uterine atony (inadequate contraction of the 
uterus after birth), and PPH can also result from uterine 
rupture, retained placental tissue, genital tract trauma 
(vaginal or cervical lacerations), and maternal coagula-
tion disorders [5].
The World Health Organization (WHO) published 
recommendations for the prevention and treatment of 
PPH in 2012 to provide evidence-informed recommen-
dations for preventing and managing PPH [5]. When 
PPH occurs, early identification of bleeding and prompt 
management with evidence-based interventions can 
avert most PPH-related severe morbidities and deaths 
[5]. However, adherence to the WHO recommended 
practices for PPH treatment remains a critical challenge 
[6]. For example, data from several low- and middle-
income countries (LMICs) show that most women with 
PPH do not receive life-saving treatment [7]. Analysis of 
WHO ‘Carbetocin Hemorrhage Prevention’ (CHAM-
PION) trial data (29,645 women; 10 countries) shows 
that only 26% (235/886) of women with a blood loss 
between 500 and 600 mL received a uterotonic drug for 
PPH treatment [7]. Alarmingly, even with a blood loss of 
1000–1100  mL, only 70% (68/96) of women received a 
uterotonic drug for the treatment of PPH [7]. Moreover, 
data from over 100 hospitals in Nigeria, Tanzania, and 
Kenya show that the real-world PPH detection rates are 
low (Nigeria 2.2%, Tanzania 2.5%, and Kenya 1.8%) [8, 
9]. These facilities typically rely on visual estimation of 
blood loss, widely recognized as inaccurate, and often 
resulting in underestimation of volume of blood lost 
[10] and thus detection of PPH.
implementation, which will be discussed and agreed with key stakeholders from each country in intervention design 
workshops.
Discussion: This formative protocol outlines our strategy for the systematic development of the E‑MOTIVE imple‑
mentation strategy. This focus on implementation considers what it would take to support roll‑out and implementa‑
tion of the E‑MOTIVE bundle. Our approach therefore aims to maximize internal validity in the trial alongside future 
scalability, and implementation of the E‑MOTIVE bundle in routine practice, if proven to be effective.
Trial registration: ClinicalTrials.gov: NCT04341662
Plain language summary 
Excessive bleeding after birth is the leading cause of maternal death globally. The World Health Organization (WHO) 
has recommended several treatment options for bleeding after birth. However, these treatments are not used regu‑
larly, or consistently for all women. A key underlying issue is that it is challenging for health workers to identify when 
women are bleeding too much, because measuring the amount of blood loss is difficult.
Maternal health experts have proposed a new clinical ‘care bundle’ for caring for women with excessive bleeding 
after birth. A care bundle is a way to group together multiple treatments (e.g. 3–5 treatments). These treatments are 
then given to the woman at the same time, or one after another in quick succession, and supported by strategies to 
improve teamwork, communication, and cooperation.
This is a research protocol for the preliminary phase of our study (“E‑MOTIVE”), which means that it is a description 
of what we plan to do and how we plan to do it. The aim of our study is to develop a strategy for how we will test 
whether the E‑MOTIVE bundle works through collaborative activities with midwives and doctors in five countries 
(Kenya, Nigeria, South Africa, Sri Lanka, and Tanzania) to develop a strategy for how we will test whether the E‑MOTIVE 
bundle works. We plan to do this by conducting interviews and surveys with midwives and doctors, and reviewing 
other research conducted on PPH to understand what works in different settings. We will discuss our research find‑
ings in a workshop, with midwives and doctors in the study countries to co‑create a strategy that will work for them, 
based on their needs and preferences.
Keywords: Maternal health, Postpartum hemorrhage, Obstetric hemorrhage, Care bundle, Formative research, 
Maternal mortality, Behavior change, Implementation, Intervention development
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This raises the question as to what factors are leading to 
low adherence to PPH recommendations in clinical prac-
tice and how adherence could be increased to improve 
evidence-based practices and quality of care. An impor-
tant shift in the current thinking is the development of 
‘clinical care bundles’ for PPH management. Clinical care 
bundles are sets of three to five discrete, evidence-based 
interventions, which are to be administered concurrently 
or in rapid succession to every person presenting with 
a specific diagnosis, with the goal of standardizing and 
expediting care [6]. Care bundles extend beyond deci-
sion-making algorithms or checklists, as care bundles 
aim to improve clinical practice by integrating discrete 
clinical interventions to be delivered together (concur-
rently or in rapid succession). Central to care bundles 
are teamwork, communication, and cooperation, both 
among healthcare workers and between healthcare work-
ers, women and their families [6, 11]. Bundle compliance 
is considered achieved when all actions are completed 
and recorded [6, 11].
In 2017, WHO facilitated a technical consultation 
to develop two care bundles of clinical interventions 
for PPH: the “first response to PPH bundle” and the 
“response to refractory PPH bundle” [6]. The interven-
tions to be considered for inclusion had to have been 
previously recommended by WHO in its PPH prevention 
and management guidelines [5, 12]. The elements in the 
first response to PPH bundle included uterotonics, intra-
venous fluids, tranexamic acid (TXA), and uterine mas-
sage. As with any clinical bundle, they are intended to be 
introduced along with supportive elements of advocacy, 
training, teamwork, communication, respectful care, and 
use of best clinical practices [6].
These supportive elements are critical components of 
the bundle: an extensive body of implementation research 
based in high income countries has identified that pas-
sive dissemination of new clinical guidelines, including 
care bundles, alone is unlikely to result in improved qual-
ity of care [13]. Indeed, implementing a new guideline or 
recommendations in practice will almost always require 
someone to do something differently. This can involve 
adopting an entirely new practice, replacing one prac-
tice with another, doing more or less of an existing prac-
tice, or discontinuing a practice altogether [14]. That is, 
implementation almost always requires behavior change, 
often in individual and collective behaviors of healthcare 
providers, as well as at organization, service delivery, and 
system levels [15]. Such behaviors are typically complex. 
This is particularly true of implementing care bundles, 
which typically involve multiple actors (e.g. healthcare 
providers), working together to deliver and perform mul-
tiple clinical actions concurrently or in rapid succession 
[16]. These behaviors are likely to be influenced by an 
equally complex set of interacting individual, socio-cul-
tural, and environmental influences. Therefore, design-
ing interventions to change clinical practice and improve 
implementation first requires understanding of the influ-
ences on current and desired behaviors in the context in 
which they occur [15, 16].
Previous research exploring influences on implementa-
tion of care bundles identified barriers related to: staffing 
levels, case acuity, lack of awareness, lack of self-efficacy, 
inappropriate expectations, overloaded or inadequate 
staff qualified to implement, lack of engagement of staff 
or management, fear of added work of record keeping, 
and fear of reprisals for not complying with bundle ele-
ments [17–19]. Conversely, factors supporting or ena-
bling implementation of bundles include: perceived 
sustainability, positive, supportive leadership and cham-
pions of the bundle, resources, training, focus on quality 
of care, teamwork, communication, and including bundle 
compliance into routine record keeping [17, 18]. How-
ever, this evidence is primarily from high-income set-
tings and concerns implementation of care bundles for 
other clinical areas (e.g. chronic obstructive pulmonary 
disease, sepsis). There is limited evidence regarding chal-
lenges to care bundle implementation in LMICs, particu-
larly in maternal health and emergency settings, which 
could include factors such as lack of staff with appro-
priate competencies, lack of essential supplies including 
medications and overburdened services.
The E‑MOTIVE study
The E-MOTIVE program of research aims to improve 
the detection and first response management of PPH 
through the implementation of a new care bundle called 
“E-MOTIVE” (Fig.  1). The E-MOTIVE bundle consists 
of (1) Early detection of postpartum hemorrhage using 
an under-buttocks, calibrated blood collection drape, 
(2) Massage of the woman’s uterus, (3) administration 
of Oxytocic drugs, (4) administration of Tranexamic 
acid, (5) administration of IntraVenous fluids, and (6) 
Examination of the woman’s genital tract and escala-
tion when necessary. E-MOTIVE will take place in three 
key phases: a formative phase, intervention phase, and 
post-intervention phase (Fig. 2). During the intervention 
phase, a parallel cluster randomized trial with a baseline 
control phase will take place, along with a mixed-meth-
ods process evaluation and cost effectiveness study. In 
the post-intervention phase, if the E-MOTIVE bundle 
is effective, clinical guidelines will be updated to reflect 
new evidence. However, as noted previously, dissemina-
tion of the bundle alone is unlikely to result in change in 
practice. Therefore, alongside the bundle, the E-MOTIVE 
program of research aims to develop, adapt, and evaluate 
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an implementation strategy to support clinician behavior 
change and uptake of the bundle in practice.
This is the focus of the formative phase (Phase 1) of 
the E-MOTIVE program of research, and the focus of 
this study protocol. E-MOTIVE Phase 1 intervention 
development will use mixed-methods to understand 
how PPH is currently managed in the study settings, and 
the potential barriers and enablers to implementing the 
E-MOTIVE bundle. This will provide a basis for design-
ing an implementation strategy with healthcare staff 
at the study sites to support uptake and delivery of the 
E-MOTIVE bundle during the trial and in wider prac-
tice. This will involve a series of workshops (described 
below) between research staff and facility-based staff in 
the countries.
We plan to use a mixed-methods approach in the form-
ative research (Fig. 2). In line with best practice guidance 
for designing and evaluating complex interventions [20], 
the formative phase will incorporate theory-based inter-
vention development, followed by a small-scale pilot and 
mixed-methods process evaluation to explore the fea-
sibility and acceptability of the intervention and imple-
mentation strategy and potential contextual modifiers. 
This will enable iterative refinement of the implementa-
tion strategy ahead of the definitive trial in Phase 2. This 
protocol focuses on describing the formative research. A 
separate protocol will be published for the feasibility pilot 
study, and the E-MOTIVE trial is registered at Clinical-
Trials.gov (NCT04341662).
Study conceptual frameworks
There are many overlapping behavior change theories, 
with limited guidance available for selecting amongst 
potentially relevant theories [21]. Thus, there have been 
efforts to synthesize behavior change theories into inte-
grated, overarching theoretical frameworks and mod-
els. One such model is the COM-B model [13] and the 
associated Theoretical Domains Framework (TDF) [22], 
which posits that in order for a desired Behavior to occur 
(i.e. clinical practice action), the individual must have the 
Capability, Opportunity, and Motivation to do so (Fig. 3) 
[13]. Both frameworks synthesize numerous theories of 
behavior change into a core set of domains (e.g. factors) 
representing individual, socio-cultural and environmen-
tal influences on behavior. Capability involves factors 
Fig. 1 The E‑MOTIVE care bundle
Fig. 2 Overview of the E‑MOTIVE research projects. The formative components of the project are outlined in this protocol. Subsequent publications 
will outline the adaptive cycles, parallel cluster randomized trial, process evaluation and cost‑effectiveness. COM-B model of behavior change 
referring to capability, opportunity, and motivation; IDIs in‑depth interviews, EtD evidence‑to‑decision frameworks, WHO World Health Organization
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such as knowledge, skills, decision making, attention, and 
memory. Opportunity concerns how our environment 
influences behavior, and includes environmental context 
factors (e.g. time, access to necessary supplies, resources, 
staffing, infrastructure) and social context (e.g. practice 
norms, professional identity, team working, pressure, 
support, role modelling). Motivation includes internal 
processes that energize and direct behavior, and factors 
such as priority, goals, perceived benefits, risk and conse-
quences, emotions, habit, incentives, and threat.
Both frameworks have been widely applied in imple-
mentation research to explore barriers and enablers 
to changing clinical practice behaviors and improving 
implementation across various clinical contexts (e.g. 
improving implementation of sepsis care bundles and 
blood transfusion practice) [15, 19, 23]. A benefit of 
COM-B and the TDF is that they are mapped to two 
associated behavioral science frameworks specify-
ing different types of intervention strategies. First, the 
Behaviour Change Wheel [13] which specifies nine 
broad intervention types (e.g. education, modelling, 
incentivization, environmental restructuring). Second, 
the Behaviour Change Technique Taxonomy, which 
specifies 93 more granular techniques for changing 
behavior (e.g. goal-setting, feedback, self-monitoring) 
[24]. There are published matrices pairing domains of 
COM-B or TDF with interventions in the Behaviour 
Change Wheel and taxonomy [25–27], thereby linking 
influences on behavior to fit-for-purpose intervention 
strategies that are likely to be relevant and effective in 
addressing different types of barriers and enablers. This 
provides a basis for guiding decision-making during 
subsequent intervention design and supporting more 
systematic, targeted and theory-based development of 
implementation interventions.
In this study, we will therefore use COM-B and the 
TDF as overarching frameworks to guide our data col-
lection and analysis when exploring influences on cur-
rent practice and implementation of the E-MOTIVE 
bundle. Using the COM-B and the TDF, we have mapped 
potential barriers to E-MOTIVE bundle implementation 
based on the available literature on bundle implementa-
tion (Additional file 1) [17–19], which we plan to iterate 
throughout the formative research. We will also use the 
domains from these frameworks to facilitate triangula-
tion and comparison of findings across data sources, par-
ticipants (i.e. healthcare professional roles), facilities, and 
countries. We will consult the Behaviour Change Wheel 
and taxonomy to identify potential implementation 
strategies to address key barriers and enablers to chang-
ing PPH practice and improving implementation of the 
E-MOTIVE bundle.
Fig. 3 Integrated study conceptual frameworks: COM‑B Model, Theoretical Domains Framework, Behavior Change Wheel [13]
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Study objectives
The overall aim of the formative phase of the E-MOTIVE 
project is to design an implementation strategy for the 
E-MOTIVE bundle. This study protocol outlines the 
formative research to support the development of the 
E-MOTIVE implementation strategy. The specific objec-
tives of the formative phase are:
1. To understand the current clinical management of 
PPH in the study facilities;
2. To explore PPH detection and management in 
healthcare providers’ current practice, how detec-
tion and treatment may be improved, and poten-
tial barriers and enablers to implementation of the 
E-MOTIVE intervention in their practice; and,
3. To identify and agree with stakeholders the imple-
mentation strategies to address identified influences 
on practices for detecting and managing PPH, and 




This study protocol outlines the mixed-methods forma-
tive phase research activities (Table  1). Given that find-
ings from the formative phase will influence the design 
and implementation of the E-MOTIVE trial, this study 
protocol only describes the formative work. There are 
four methodological components of the formative phase:
1. Qualitative research (in-depth interviews (IDIs);
2. Quantitative survey;
3. Systematic reviews; and
4. Stakeholder consultation and design workshops.
The formative study will take place in five countries: 
Kenya, Nigeria, South Africa, Sri Lanka and Tanza-
nia. Table  2 presents an overview of the country’s bur-
den of PPH. In line with the Medical Research Council 
Guidance for Process Evaluations [28], we will balance 
in-depth qualitative data collection in a sub-sample of 
three countries, with broader quantitative data collection 
across all five countries.
Qualitative research methods
Study sites and participants
This qualitative IDI study will be conducted in a purpo-
sive sample of three health facilities per country across 
three countries (Kenya, Nigeria, South Africa), for a total 
of nine health facilities. These health facilities have all 
met the inclusion criteria for the E-MOTIVE trial, and 
thus are representative of the types of health facilities 
participating in the trial. The health facilities included as 
formative research sites will be excluded from participa-
tion in the clinical trial, as they may have been primed or 
biased as a result of taking part in the formative research. 
The health facilities to be included as sites in the quali-
tative study will be selected using maximum variation 
sampling to ensure variation in the size of the facility, 
location, representativeness of facility characteristics eli-
gible for main trial, and other key variables.
Healthcare providers currently working on the mater-
nity wards will be included as participants. This includes 
midwives, nurses, junior doctors, non-physician clini-
cians, medical officers, residents or trainees, and obstetri-
cians. Healthcare administrators and managers in charge 
of the maternity wards or health facilities will be included 
as participants. This may include the head of obstetrics, 
matron-in-charge, or medical or clinical director. All par-
ticipants will be capable of responding to the interview 
questions in English.
Participant sampling and recruitment
In line with qualitative sample size guidelines based on 
principles of thematic data saturation [29], we will aim 
to recruit an initial sample of ten to fifteen participants 
per country across the three countries (n = a total of 45 
participants: n = 15 participants per country, n = 5 par-
ticipants per health facility). We will analyze data in par-
allel with data collection, monitoring for thematic data 
saturation as we go, and adjust the sample size as neces-
sary (e.g. discontinuing further interviews if saturation is 
deemed achieved, or conducting additional interviews as 
needed until saturation is deemed achieved). Maximum 
variation sampling will be used to achieve a stratified 
sample without random selection and to ensure hetero-
geneity of research participants. This method uses pre-
specified variables to stratify the sample and encourages 
the recruitment and sampling based on diversity. In each 
of the selected health facilities, healthcare providers will 
be sampled based on their cadre, such as nurse, midwife 
or doctor. The country investigators and research teams 
will facilitate contact with potentially eligible healthcare 
providers and administrators at their place of work in the 
study health facilities. Each individual will be provided 
with an information sheet about the study, invited to par-
ticipate by the research team, and if they agree, asked to 
provide consent.
Study instruments
We have designed interview topic guides and surveys 
based on COM-B and the TDF to explore factors influ-
encing current detection and management of PPH, by 
ensuring we have at least one question per domain of the 
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frameworks. The study instrument will be a semi-struc-
tured discussion guide (Additional file  2). This will be 
structured according to three broad sections:
1. How PPH is currently detected and managed for vag-
inal birth;
2. Factors influencing current practice for PPH man-
agement. These questions will be structured around 
the domains of the COM-B model (capability, oppor-
tunity, motivation) [13]; and
3. Factors potentially influencing the implementation 
of the E-MOTIVE bundle, structured around the 
domains of the COM-B model.
The discussion guide has been developed by a team of 
social and behavioral scientists, obstetricians, and mid-
wives to ensure clinical relevance and use of behavior 
change theory. The IDIs will be piloted prior to data col-
lection, as part of training the research teams, and revi-
sions made to improve clarity.
Study procedures and follow‑up
All IDIs will be conducted face-to-face, or via Zoom or 
telephone (currently, COVID-19 restrictions do not allow 
for face-to-face data collection outside of data collectors’ 
home institution), in English, and take place in a pri-
vate setting in the health facility where social distancing 
Table 2 Burden of postpartum hemorrhage and current management in the E‑MOTIVE study sites
Global estimates indicate that between the years 2000 and 2017 global maternal deaths reduced by 35%, from 451 000 to 295,000 maternal deaths in 
2017 [40]. During this 17 year period the global maternal mortality dropped by 2.9% on average each year. The global lifetime risk of maternal mortal‑
ity in 2017 was estimated at 1 in 190 [40]
Nigeria
Nigerian women have a 1 in 21 lifetime risk of maternal death, much higher than the global average. In 2017, 23% of global maternal deaths occurred 
in Nigeria alone, with 67,000 reported maternal deaths. Nigeria had the fourth highest maternal mortality ratio (MMR) globally in 2017, with 917 
deaths per 100,000 live births (Uncertainty Interval (UI) 658 to 1320). With an average Annual Reduction Rate (ARR) point estimate of less than 1.6% 
(UI ‑0.8 to 3.5) between 2000 and 2017, Nigeria’s annual rate of reduction in maternal deaths per 100,000 live births dropped at a lower rate than the 
global average during the same time period [40]. Results from a retrospective study of medical deaths in a tertiary institution in Northern Nigeria 
indicated that PPH accounted for 14.2% of 112 maternal deaths during a five year period [41]. Further secondary analysis research concluded that 
PPH was a significant contributor to obstetric hemorrhage and severe maternal outcomes in Nigerian hospitals. PPH occurred in 2.2% of births over a 
1 year period, and was the most frequent obstetric complication across all facilities [9]
Tanzania
The United Republic of Tanzania reported approximately 11,000 (UI 8,100 to 14,000) maternal deaths in 2017, this was the fifth highest number of 
maternal deaths worldwide. Women in Tanzania are estimated to have a 1 in 36 risk of maternal death. Figures indicate that in 2017, Tanzania was esti‑
mated to have an MMR of 524 deaths per 100,000 live births (UI 399 to 712), as well as an ARR point estimate of 2.9% (UI 0.9 to 4.4) between 2000 and 
2017, in line with the global average [40]. Retrospective research from 34 public hospitals in Tanzania found that of the 1,987 maternal deaths over a 
ten year period (2006–2015), 34% were due to eclampsia, followed by 24.6% due to obstetric hemorrhage. During this ten year period, the number 
of maternal deaths increased, with MMR increasing from 40.24 in 2006 to 57.94 per 100, 000 live births in 2015 [42]. Further descriptive retrospective 
tertiary research between 2003 and 2012 at a single center in Northern Tanzania reported an MMR of 492.1 per 100,000 live deliveries, in line with 
previously reported WHO mortality estimates. Postpartum hemorrhage was found to be the leading cause of maternal death during the study period, 
accounting for 19.2% of maternal mortality [43]
South Africa
Women in South Africa have a lifetime risk of maternal death of 1 in 330; this risk is lower than the estimated global average. In 2017, the number of 
maternal deaths in South Africa was estimated to be approximately 1,400. During this year South Africa was estimated to have an MMR point of 119 
deaths per 100,000 live births (UI 96 to 153), and an ARR point estimate of 1.7% (UI 0.1 to 3), indicating that the annual rate of reduction fell at a lower 
rate than the global average between the years 2000 and 2017 [40]
The most recent Saving Mothers triennial report, by the National Committee for Confidential Enquiry into Maternal Deaths (NCCEMD) in South Africa, 
gave obstetric hemorrhage as the cause of 624 or 16.9% of the total deaths between the years 2014 and 2017, making obstetric hemorrhage the 
third most common cause of maternal death during this period, with 89.5% assessed to have been preventable by better care [44]
Kenya
Kenyan women have a 1 in 76 risk of maternal death during their lifetime, higher than the global average risk. In the year 2017, it was estimated that 
5,000 maternal deaths occurred in Kenya, with an MMR point of 342 deaths per 100,000 live births (UI 253 to 476) during this period. Between the 
years 2000 and 2017 the WHO estimated that Kenya had an ARR point of 4.3% (UI 2.4 to 5.9), indicating a lower rate of reduction in maternal deaths 
than the global average during the same time period [40]. In 2017, the Kenyan Ministry of Heath produced their first Saving Mothers Lives report, 
an enquiry into maternal deaths in Kenyan country and national referral hospitals during the year 2014. Obstetric hemorrhage was found to be the 
underlying cause of 192, or 40% of the 945 maternal deaths during this period [45]
Sri Lanka
Sri Lankan women have a lifetime risk of maternal death of 1 in 1,300, and are at lower risk of death than the global average. In 2017, 120 maternal 
deaths were reported in Sri Lanka. Figures estimate that in 2017, Sri Lanka had an MMR of 36 deaths per 100,000 live births (UI 31 to 41), as well as an 
ARR point estimate of 2.2% (UI 1.7 to 3.5) between 2000 and 2017 [40]. This indicates that the annual rate of reduction in Sri Lanka dropped at a lower 
rate than the global average over this 17‑year period. Data from the most recent National Maternal Mortality Review from the Family Health Bureau, 
Ministry of Health Care and Nutrition of Sri Lanka reported that, in 2016 obstetric hemorrhage was the cause of 13.4% of maternal deaths in Sri Lanka, 
and was the leading cause of maternal death during this period. More specifically, PPH was reported as the cause of death in 8 out of 112 (7.1%) 
maternal deaths reported in Sri Lanka during this year (46)
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and hygienic behaviors can be maintained (or at home if 
via Zoom or telephone), which is typical and appropri-
ate in each of the study settings. All interviews will be 
digitally recorded on an encrypted device, and the inter-
viewer will take handwritten field notes containing both 
descriptive information (settings, actions, behaviors) and 
reflective information (thoughts, ideas, questions, con-
cerns) about the interview. At the start of the IDIs, par-
ticipants will be asked to confirm that they have received 
the information sheet and signed the consent form. IDIs 
are expected to last approximately 45–60 min and will be 
conducted by a trained research midwife or local social 
science researcher.
Once the IDIs are conducted, the study participants 
will not be followed up. The exception is if the partici-
pants in the qualitative study also participate in either 
the quantitative survey or stakeholder consultation and 
design workshops (described below). However, partici-
pation in the qualitative study will not be contingent on 
participating in any subsequent research activities, and 
responses will not be linked by participant or any identi-
fying information.
Data management and quality assurance
Prior to data collection, a multi-day training session will 
be conducted for all the research teams, including coun-
try principal investigators, data collectors, and other 
research team members. The training session will include 
the study objectives, data collection procedures, practice 
sessions with the tools, and ethical considerations. The 
international research team and the principal investiga-
tors in each country, will train the research teams. This 
training will take place via Zoom due to COVID-19 travel 
restrictions. During the data collection period, the coun-
try principal investigators will be in consistent communi-
cation with the interviewers in the field to respond to any 
issues that arise during data collection.
All digital recording will be transcribed verbatim into 
English using a structured format. Transcription will be 
done by either the data collector or a professional tran-
scription service that is General Data Protection Regu-
lation (GDPR) compliant. Verbatim transcription will 
be performed close to the time of the completion of 
the interviews to maintain the uniqueness of the inter-
view without loss of themes. Observations and assess-
ment during the interviews will be written up as field 
notes and integrated into the transcripts. At the point 
of transcription, data will be anonymized; no identifi-
able information about the participants will be included 
in the written transcripts. Participants and sites will be 
given identifying numbers for reference. Transcription 
will occur in parallel to data collection and will be shared 
on an on-going basis with the international research 
team to ensure the quality of the data and to determine 
if certain themes need to be further explored. The inter-
national research team will be responsible for reviewing 
transcripts as they are shared in order to provide ongo-
ing feedback on topics that could be probed more deeply 
during future interviews, identification of areas for 
improvement, problem-solving, and facilitating dialogue 
with the country teams regarding saturation of themes.
Data analysis plan
Anonymized transcripts will be analyzed using a com-
bined inductive thematic and deductive framework 
analysis [30]. We plan to first use an inductive thematic 
analysis approach [31] to allow themes to emerge natu-
rally from the data. Then we will use a deductive frame-
work based on the study objectives and topic guide to 
map the generated themes to key areas related to PPH 
detection and management. Lastly, we plan to code the 
emergent themes representing factors affecting imple-
mentation (barriers, facilitators, neutral responses) to the 
domains of the underlying theoretical framework (COM-
B). We will deductively code the generated themes to 
the relevant COM-B domain that they are judged to best 
represent. For example, an instance of ‘lack of clear com-
munication and teamwork’ would be mapped to ‘social 
Opportunity,’ ‘fear and stress managing PPH’ would be 
mapped to ‘automatic Motivation’, and ‘lack of ready 
access to oxytocin’ would be mapped to ‘physical Oppor-
tunity’. We expect that these themes will represent key 
influences or factors affecting PPH detection and man-




This will be a cross-sectional, electronic survey con-
ducted in all E-MOTIVE study hospitals (n = 80) across 
five countries: Kenya, Nigeria, South Africa, Sri Lanka, 
and Tanzania. These sites have been selected for partici-
pation in the E-MOTIVE trial, and will participate in the 
survey, prior to the trial’s inception. We plan to engage a 
variety of participants with the survey to gather a wide 
range of opinions. All potential participants will cur-
rently work within the maternity wards of the study facil-
ities, including (but not limited to): midwives, nurses, 
junior doctors, medical officers, residents, obstetricians, 
and health managers. Potential participants must be 
capable of reading and responding to the survey ques-
tions in English; there are no restrictions on other demo-
graphic characteristics of participants, including: age, 
gender, race, ethnicity, or sexual orientation. Individuals 
who are unable or unwilling to give informed consent 
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to participate will not be able to take part, and patients 
and family caregivers are not eligible to participate in this 
survey.
Participant recruitment and sampling
The country principal investigators and facility research 
coordinators will facilitate contact with the health care 
providers and managers in each study facility. At each 
health facility, the facility coordinator will obtain a list of 
potential participants and their email addresses meeting 
the eligibility criteria at their site. Individualized email 
links to complete the survey will be sent to each eligible 
participant, and reminders to complete the survey will 
be sent weekly for two weeks. Participants will also be 
invited to take part, if they have not already, at the study 
sites, during site visits by the country principal investiga-
tors. We have chosen this method of recruitment in order 
to be able to calculate response rates, understand the 
denominator, and to facilitate monitoring of responses 
and follow-up. Responses will not be able to be linked 
back to an individual’s email address or name.
If participants are willing to take part, they will be 
asked to provide written consent via the online survey 
platform (SmartSurvey) before they begin. The first page 
of the electronic survey will be the participant informa-
tion sheet. The second page of the electronic survey will 
be the informed consent form, and a tick box to say ‘I 
consent to all of the above statements’ or ‘I do not con-
sent to all of the above statements’ Participants will be 
asked to complete the survey independently and in a set-
ting where they feel comfortable to give honest responses 
without fear of repercussions.
Maximum variation sampling will be used to achieve a 
stratified sample without random selection, and to ensure 
heterogeneity of research participants. This method 
uses pre-specified parameters to stratify the sample 
and encourages the recruitment and sampling based on 
diversity. In each of the 80 study facilities, healthcare 
professionals will be sampled based on their cadre. We 
expect the type or designation of health care profession-
als to vary by facility, but at the minimum would include 
specialists, medical officers, and midwives/nurses. We 
plan to sample nine to ten participants per study facility, 
including five midwives or nurses, three medical officers 
or junior doctors, and two obstetric specialists, for a total 
of (n = 720–800) across all sites and countries.
Study instruments
The study instrument will be an online quantitative sur-
vey, hosted by SmartSurvey (Additional file 3). The sur-
vey has been developed by a team of social and behavioral 
scientists, obstetricians and midwives to ensure clinical 
relevance and use of behavior change frameworks. The 
survey will be piloted prior to data collection, as part 
of training the research teams. The survey is expected 
to take the participants approximately fifteen to twenty 
minutes to complete. The overarching structure and con-
tent of the survey mirrors the qualitative interview guide 
to facilitate triangulation between the two data collection 
methods and data sources. The survey will cover the fol-
lowing domains:
1. Sociodemographic information (role, years of experi-
ence, country and place of employment);
2. How PPH is currently detected and managed for vag-
inal birth, including clinical vignettes or scenarios;
3. Factors influencing current practice for PPH man-
agement. These questions will be structured around 
the domains of the COM-B model (capability, oppor-
tunity, motivation) [13]; and
4. Potential barriers and enablers to implementing the 
E-MOTIVE bundle, structured around the domains 
of the COM-B model.
Response options will include a combination of dichot-
omous (yes/no or true/false), Likert scales, open-ended 
short answer response, and multi-option format. The 
survey will be made available in both a web and mobile 
friendly format, to enable participants to take part on 
their own devices with ease.
Study procedures and follow‑up
Participants will be invited to take part in an electronic 
survey study using a SmartSurvey web link. Participants 
will be asked during the survey if they would like to hear 
the results of the survey once they have been collated and 
interpreted, and will be given the option to provide a con-
tact email if they so choose. If they choose to share their 
contact email, their email address will be stored sepa-
rately from their survey responses to protect anonymity.
Once the surveys have been completed, study partici-
pants may have additional contact with the research team 
through two potential avenues. First, if the participant 
chooses to share their contact email, we will share the 
study results with them. Second, if the participant is still 
employed at the study site during the stakeholder con-
sultation and design workshops or the subsequent trial, 
they may be involved in research workshops, developing 
implementation strategies, etc. However, they will not 
be identified as participants in the survey and their deci-
sion to participate or not in the survey will have no bear-
ing on their future involvement in the trial. When data 
collection is complete, the data will be analyzed and the 
results interpreted. These findings will then be used to 
inform the development of the E-MOTIVE implementa-
tion strategy.
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Data management and quality assurance
All data collected through SmartSurvey is registered 
under the General Data Protection Regulation 2018. 
Secure Sockets Layer encryption will be added to any 
survey, which enables an encrypted link between a web 
server and a browser to be established. This ensures 
that all data passed between the web servers and 
the browsers remain private and integral. All data is 
stored and backed up on United Kingdom-based serv-
ers, and will not be accessed nor shared without prior 
permission.
Country PIs will be in frequent communication with 
the E-MOTIVE formative research team in order to 
respond to any issues that arise during data collec-
tion. Halfway through data collection in each country, 
the E-MOTIVE formative study team will review all 
data collected up to that point to ensure data quality. 
Completion rates will be monitored, non-respondents 
will receive a maximum of two reminder emails asking 
them to complete the survey. Country principal investi-
gators will also follow up with study sites to maximize 
response to the survey.
Data analysis plan
Once data collection is complete and results have been 
exported from SmartSurvey, data will be cleaned and 
prepared for analysis in Stata (StataCorp. 2019. Stata 
Statistical Software: Release 16. College Station, TX: 
StataCorp LLC). Any missing data or responses of ‘not 
sure or other’ will be coded to allow this data to be 
excluded from the analysis where appropriate. Quanti-
tative survey data will be summarized using descriptive 
statistics as appropriate. Cross-tabulation will be used 
to describe practices for PPH detection and manage-
ment, and perceptions of the E-MOTIVE intervention 
for PPH management. Results will be cross-tabulated 
and filtered to allow comparison of results by demo-
graphic subgroup, including job role, facility type or 
level, and country. This data will help to establish a 
benchmark or baseline of practices for PPH manage-
ment and perceptions of the E-MOTIVE intervention 
and implementation strategy, to allow comparison 
of practices and perceptions over the course of the 
E-MOTIVE trial, and post-trial. For the theory-based 
items exploring factors influencing PPH detection and 
management, there will be at least two to three items 
per domain of the COM-B model. To create a sub-scale 
score for each domain of COM-B, we will calculate an 
average response score across items corresponding to 
that domain [32]. Open-ended or short answer ques-
tions will be analyzed using quantitative content analy-
sis [33].
Systematic reviews
In addition to the primary research outlined above, we 
plan to conduct several systematic reviews during the 
formative phase to inform the development of the imple-
mentation strategy. First, we plan to conduct a Cochrane 
qualitative evidence synthesis (systematic review of 
qualitative evidence) to describe and explore the percep-
tions and experiences of women, community members, 
lay health workers, and skilled healthcare providers who 
have experience with PPH, or with preventing, identify-
ing and managing PPH, in both community and health 
facility settings [34]. This qualitative evidence synthe-
sis will supplement our primary qualitative research by 
including the perspectives of women and communities, 
and understanding the complexities of PPH detection 
and management further upstream (e.g. for women giv-
ing birth at home, in the community, or in primary health 
facilities). The Cochrane review protocol is published 
elsewhere [34].
Stakeholder consultation and design workshops
Design of the E-MOTIVE bundle implementation strat-
egy based on the findings of the formative research will 
involve two stages: (1) triangulation of findings across 
data sources by the research team, and (2) stakeholder 
consultation workshops to refine and adapt the strategy 
to each country’s local context. The methods for each are 
described below.
Research data triangulation
We are using multiple methods to collect data on factors 
influencing PPH detection and management across coun-
tries, and from the perspective of different healthcare 
professionals. It is therefore important to compare and 
contrast the findings across these data sources and par-
ticipant groups using standardized triangulation meth-
ods [35, 36]. This will involve the E-MOTIVE research 
team tabulating findings across data sources and looking 
for areas of agreement, disagreement, and silence [35]. 
We will compare findings at three levels: (1) across data 
sources (interviews vs. surveys vs. systematic review); (2) 
across countries; (3) across healthcare professional roles 
(e.g. nurses, midwives, doctors). This will help identify 
areas for further discussion and clarification in the work-
shops (see Section: Stakeholder consultation and design 
workshops below).
It will also inform decisions around components of 
the implementation strategy that can be standardized/
shared across countries, versus those that need to be 
tailored to each country and/or participant group. Find-
ings from the triangulation exercise will highlight key 
influences on current practice and barriers and enablers 
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to implementation, which represent potential targets for 
implementation strategies. To generate potential recom-
mendations for strategies, we will consult the aforemen-
tioned tools that pair the COM-B and TDF frameworks 
as part of the Behaviour Change Wheel to identify poten-
tial types of strategies that are likely to be relevant and 
effective in addressing identified influences, and barriers 
and enablers. We will generate descriptions of potential 
strategies, to be presented and discussed at stakeholder 
consultation workshops (see 5.3.2. below). Where pos-
sible, we will build upon existing strategies, such as the 
Jhpiego “Bleeding after Birth” training package for PPH 
management.
Stakeholder consultation and design workshops
We will then host country specific stakeholder consul-
tation and design workshops that bring together the 
E-MOTIVE international research team and local col-
laborators. We have already identified a preliminary 
implementation strategy based on the available evidence 
on barriers and enablers to bundle implementation in the 
broader literature (summarized and mapped to COM-B 
in Additional file 1). During the workshops, we will refine 
the implementation strategy based on formative findings 
specific to the study country and PPH contexts.
We anticipate that there will be a standardized set of 
components (Fig.  1). However, how these are delivered 
and operationalized may be tailored and refined to each 
country’s setting and specific influences on PPH detec-
tion and management. For example, all countries may 
receive an element of standardized training, with tailor-
ing in terms of how the training is scheduled, which cadre 
of healthcare workers attend the training, and how the 
training is delivered. The workshops will be attended by 
the E-MOTIVE international research team, E-MOTIVE 
country teams, and hospital representatives (doctors, 
midwives). Each participant will be given a study infor-
mation sheet and asked to sign a consent form prior to 
participating in the stakeholder consultation and design 
workshops. At present, it is planned that these workshops 
will be held virtually, using platforms such as Zoom due 
to COVID-19 restrictions. However, if safe and appropri-
ate, these may be held face-to-face in each country, or 
using a hybrid model of Zoom and face-to-face.
The workshop will begin with the E-MOTIVE research 
team presenting a summary of why PPH is a priority 
issue to address, an overview of the broader EMOTIVE 
program of research, and the proposed EMOTIVE bun-
dle. We will then briefly summarize the methods for the 
formative research and the proposed implementation 
strategies generated in the previous step. Each strategy 
will be discussed in turn. For each strategy, we will first 
outline what the proposed strategy entails, the evidence 
from the broader literature supporting the strategy, and 
relevant evidence from the formative research—spe-
cifically, what identified challenges (i.e. barriers and ena-
blers) the strategy aims to address. We will ask a series 
of open and closed questions to participating stakehold-
ers to explore how acceptable and feasible the proposed 
strategy is, as well as how the implementation strategy 
could best be delivered, tailored, or adapted to their local 
contexts. We will audio-record discussions for subse-
quent analysis. Then the final agreed upon implementa-
tion strategy will be summarized using the “template for 
intervention description and replication” (TIDieR) tem-
plate, a guideline for describing and reporting complex 
interventions (e.g. TIDieR checklists; [37]).
Data generated from the workshops will include audio-
recordings, transcriptions, and field notes of the discus-
sions. Transcripts and field notes will be analyzed using 
inductive thematic synthesis. These findings will be used 
to: (a) systematically and transparently report the inter-
vention development process; and (b) to finalize the 
manual of operations for the trial, intervention materials 
and protocols, including training.
Ethical considerations
We have received ethics approvals for this study (see 
Declarations: Ethics approval and consent to participate 
for list of approvals). The study will employ broad partici-
pation criteria to be as inclusive as possible of all cadres 
of healthcare providers. Therefore, specific sub-groups 
of healthcare providers are not disadvantaged through 
being unable to participate in the study. All potential par-
ticipants in both the qualitative and survey components 
will receive information about the study in plain English, 
conforming to ethical requirements for research involv-
ing human subjects. The language will be easy to under-
stand and free of technical jargons. Participants will be 
given sufficient time to reflect on the information and ask 
questions. Those who consent to participate in the study 
will be requested to sign the informed consent form and 
it will be made clear that they are free to withdraw from 
the study at any stage without risk of any negative conse-
quences. All participants will be free to refuse to partici-
pate or stop participating at any time, confidentially, and 
without prejudice. There will be no form of deception in 
this study.
In the qualitative interviews, the data collector 
(research midwife and/or in-country social scientists) 
will facilitate the informed consent process and the paper 
(hard copy) signed consent forms will be maintained. In 
the online survey, consent will be obtained via the online 
platform. The contact details of the local investigators 
including email address or telephone numbers will be 
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made available to the participants in both the qualita-
tive and survey components, should they require further 
information and assistance.
Study participants will not receive any compensation 
for their participation. We expect that the qualitative 
interviews will take place during their shift at work or 
from home (if by telephone or Zoom), and they may be 
provided with light refreshment (such as a cold bever-
age). Survey participants will not receive any remunera-
tion for their time.
Discussion
This formative study aims to collect information to 
inform the design and implementation of a cluster ran-
domized controlled trial and process evaluation on PPH 
early detection and primary response management, 
which ultimately has the potential to reduce maternal 
mortality and severe morbidity in some of the countries 
with the highest PPH burden globally. Understanding 
current clinical practice of detection and management of 
postpartum hemorrhage will provide critical information 
to ensure that the trial is not only feasible in the study 
settings, but could be successfully implemented. Under-
standing potential barriers and enablers and involving the 
facility health care professionals will help tailor and con-
textualize the Emotive Bundle implementation strategy.
Expected study outcomes
In this formative research, we aim to develop an imple-
mentation strategy for the E-MOTIVE bundle. The form-
ative research will provide deep understanding of current 
clinical management practices of PPH, how detection 
and management can be improved, and how implement-
ing the E-MOTIVE bundle can lead to improved practice. 
Given the complexities of changing behaviors in order to 
implement new guidelines and care bundles, using the 
COM-B and TDF as guiding theoretical frameworks will 
help us consider the broad range of potential influences 
on implementation and identify the types of implemen-
tation strategies that are likely to be most relevant and 
effective to target the key influences of appropriate PPH 
detection and management and implementation of the 
E-MOTIVE bundle. Moreover, by considering potential 
barriers and enablers to implementation from the start of 
the E-MOTIVE project, we expect to maximize the like-
lihood of a successful intervention, including real-world 
applicability and effectiveness.
Strengthening international collaborations
The E-MOTIVE Research Group brings together a 
diverse team of clinicians, multi-disciplinary researchers, 
and implementation partners from the University of Bir-
mingham, WHO, University of California San Francisco, 
University College London, University of Melbourne, 
Jhpiego, Concept Foundation, Ammalife Charity, Uni-
versity of Liverpool, University of Nairobi, University 
of Cape Town, University of the Witwatersrand, Bay-
ero University Kano, Nigeria, Muhimbili University of 
Health and Allied Sciences and University of Kelaniya 
and University of Jaffna. Each partner brings their own 
unique expertise and perspectives to the E-MOTIVE 
Research Group, and this expertise is diffused to the 
other partners.
Main problems anticipated and proposed solutions
It is possible that healthcare providers and management 
may not initially support the implementation of the 
E-MOTIVE bundle in their workplace, and may there-
fore be reluctant to take part in research as they may 
feel unable to express their concerns. However, the study 
team will remind participants that their names will not 
be linked to any responses and encourage the study par-
ticipants to uphold the confidentiality among their peers. 
We will also remind participants that their decision 
regarding whether or not to take part in the formative 
research will not be shared with their peers or line man-
agers. Also, management teams (local champions) will 
be established in each facility to ensure that top manage-
ment is aware and supportive of the research. The study 
team will rely on the country partners and facility staff to 
identify potential participants.
The E-MOTIVE formative study will be implemented 
during COVID-19 times, meaning that additional pre-
cautions will need to be in place for both the research 
team and participants. Depending on local conditions 
and current restrictions, IDIs may take place over Zoom 
or telephone instead of face-to-face. Where possible, the 
local research team will minimize face-to-face contact 
with each other and research participants.
Next steps following formative phase
Following the stakeholder consultation and design work-
shops, we plan to field-test the feasibility of the provi-
sional E-MOTIVE implementation strategy, bundle, and 
tools in two health facilities in each of the five countries 
(ten health facilities total), over up to two adaptive cycles. 
Each adaptive cycle will last approximately three months. 
During the adaptive cycle, we will conduct a small-scale 
mixed-methods process evaluation to explore two key 
implementation outcomes [38] relevant to feasibility and 
pilot studies, which need to be optimized before pro-
gressing to the full trial: fidelity (i.e. extent to which the 
intervention is delivered and engaged with as intended) 
and acceptability. Following the adaptive cycle, we will 
convene a meeting with the multi-disciplinary research 
team members and local clinical collaborators to agree 
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which issues identified need to be addressed, and how 
best to refine or add to the existing implementation 
materials. If needed, we may progress to a second adap-
tive cycle to test the adapted implementation strategy, 
and further discuss and adapt the intervention as needed. 
The design of the implementation strategy, adaptive cycle 
methodology, and results of the mini-process evaluation 
will be described in subsequent publications.
Applicability and dissemination of results
The results of this formative research will inform the 
design and implementation of the E-MOTIVE trial and 
the process evaluation to be conducted in similar set-
tings. The qualitative and survey components will pro-
vide the initial interaction with providers similar to those 
working in the study sites to better understand current 
practice around detection and management of postpar-
tum hemorrhage. This evidence will then ensure that the 
trial implementation plan is feasible, appropriate, and 
applicable to the context.
We describe our systematic approach to formative 
research, which considers potential barriers to imple-
mentation prior to the start of the E-MOTIVE trial. This 
systematic approach enables us to design strategies to 
improve implementation during the trial and beyond. 
During the trial, this means we are maximizing the likeli-
hood of the interventions being delivered with fidelity If 
healthcare providers do not use the bundle or if the bun-
dle is not implemented as intended, we have little or no 
chance of testing the impact of the bundle on reducing 
PPH-associated mortality and complications [39]. There-
fore, a key implication of the formative phase is the oppor-
tunity to improve the internal validity of the E-MOTIVE 
randomized clinical trial, noting its complexity (> 300,000 
women across 80 health facilities in five countries).
Moreover, and in line with MRC guidance for devel-
oping and evaluating complex interventions [20], this 
formative protocol outlines our strategy of consider-
ing implementation from the start of the E-MOTIVE 
research program. This includes consideration of what 
it would take to support roll-out and implementation of 
the E-MOTIVE bundle in practice, rather than first eval-
uating the bundle in a trial context then thinking about 
implementation afterwards. Our approach outlined in 
this protocol therefore aims to maximize scalability and 
implementation of the E-MOTIVE bundle in the future.
Findings from this formative study will be disseminated 
to key stakeholders through a variety of outputs includ-
ing journal articles, presentations, and evidence briefs 
as appropriate. Follow the E-MOTIVE study on Twitter 
@EmotiveTrial.
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